InvestorsHub Logo

Amatuer17

05/21/16 6:57 PM

#2685 RE: Titan V #2684

Actually this article really confirms what CYDY has seen in adjunct therapy trial - much slower enrollment - despite having 25 sites activated - 8 were closed maybe due to low participation.

Dr P has confirmed that they have contracted same CRO for monotherapy - this could mean that existing sites will be used for enrollment - this could create conflict of enrollment between 2 sites - that may be reason why Dr P said that monotherapy enrollment may complete 1st. They may divert patients to monotherapy before adjunct therapy

Inoviorulez

05/21/16 9:05 PM

#2686 RE: Titan V #2684

Yah but would existing patients want to take 7 pills everyday 7 days a week? That's 49 pills per week and that is damaging on the liver.

Or would it be more prudent to take one weekly injection with Pro 140? With no toxicity, and no liver damage.

If you look up Truvada from Gilead sciences and other HIV pill drugs the number one concern is liver toxicity, nausea, vomiting, etc. Why go through all that when you can take Pro 140? IMO even existing patients will switch